Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

What is CD4+CD56+ malignancy and how should it be treated?

Bone Marrow Transplantation volume 32, pages 637–646 (2003)Cite this article

Summary:

CD4+CD56+ malignancy is a rare neoplasm with a typical clinical pattern, an aggressive course and high early relapse rate despite good initial response to chemotherapy. In this review, the impact of different therapeutic approaches on clinical outcome has been studied. We evaluated 91 published cases and our own six patients in terms of clinical features, immunophenotype/cytogenetics and treatment outcome. Treatment was divided into four groups: (A) chemotherapy less intensive than CHOP; (B) CHOP and CHOP-like regimens; (C) therapy for acute leukemia; (D) allogeneic/autologous stem cell transplantation. The median overall survival was only 13 months for all patients. Patients with skin-restricted disease showed no difference in the overall survival from patients with advanced disease (17 and 12 months, respectively). Age ⩾60 years was a negative prognostic factor. Age-adjusted analysis revealed improved survival after high-dose chemo/radiotherapy followed by allogeneic stem cell transplantation when performed in first complete remission. This therapeutic approach should be recommended for eligible patients with CD4+CD56+ malignancy. For older patients the best treatment option is still unknown.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 2
Figure 1
Figure 3
Figure 4

References

  1. Chan JK . Natural killer cell neoplasms. Anat Pathol 1998; 3: 77–145.

    CAS  PubMed  Google Scholar 

  2. Jaffe ES, Chan JKC, Su I-J et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103–111.

    Article  CAS  Google Scholar 

  3. Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 214–215.

    Google Scholar 

  4. Rüdiger T, Weisenburger DD, Anderson JR et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Ann Oncol 2002; 13: 140–149.

    Article  Google Scholar 

  5. Petrella T, Comeau MR, Maynadié M et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmocytoid monocytes. Am J Surg Pathol 2002; 26: 852–862.

    Article  Google Scholar 

  6. Bachetoni A, Lionetti P, Cinti P et al. Homing of CD4+CD56+ T lymphocytes into kidney allografts during tubular necrosis or rejection. Clin Transplant 1995; 9: 433–437.

    CAS  PubMed  Google Scholar 

  7. Barnaba V, Franco A, Paroli M et al. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a helper type 1 profile of cytokine secretion in the liver of patients chronically infected with hepatitis B virus. J Immunol 1994; 152: 3074–3087.

    CAS  PubMed  Google Scholar 

  8. Chaperot L, Bendriss N, Manches O et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001; 97: 3210–3217.

    Article  CAS  Google Scholar 

  9. Hayashi K, Nakamura S, Koshikawa T et al. A case of neural cell adhesion molecule-positive peripheral T-cell lymphoma associated with human T-cell lymphotrophic virus type 1 showing an unusual involvement of the gastrointestinal tract during the course of the disease. Hum Pathol 1994; 25: 1251–1253.

    Article  CAS  Google Scholar 

  10. Adachi M, Maeda K, Takekawa M et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994; 47: 278–282.

    Article  CAS  Google Scholar 

  11. Petrella T, Dalac S, Maynadié M et al. and the Groupe Français d’Etude des Lymphomes Cutanés (GFELC). CD4+ CD56+ cutaneous neoplasm: A distinct hematological entity? Am J Surg Pathol 1999; 23: 137–146.

    Article  CAS  Google Scholar 

  12. Savoia P, Fierro MT, Novelli M et al. CD56-positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol 1997; 137: 966–971.

    Article  CAS  Google Scholar 

  13. Brody JP, Allen S, Schulman P et al. Acute agranular CD4-positive natural killer cell leukemia. Cancer 1995; 75: 2474–2483.

    Article  CAS  Google Scholar 

  14. Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study of CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am J Surg Pathol 1995; 19: 284–296.

    Article  CAS  Google Scholar 

  15. Kobashi Y, Nakamura S, Sasajima Y et al. Inconsistent association of Epstein–Barr virus with CD56 (NCAM)-positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Histopathology 1996; 28: 111–120.

    Article  CAS  Google Scholar 

  16. Savilo E, Meyer RM, Soamboosrup P et al. CD2+, CD3−, CD56/NCAM+ malignant lymphoma with TCRβ gene rearrangement: a case report. Am J Hematol 1995; 50: 209–214.

    Article  CAS  Google Scholar 

  17. Dummer R, Potoczna N, Häffner AC et al. A primary cutaneous non-T, non-B CD4+, CD56+ lymphoma. Arch Dermatol 1996; 132: 550–553.

    Article  CAS  Google Scholar 

  18. Emile J-F, Boulland M-L, Haioun C et al. CD5− CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87: 1466–1473.

    CAS  PubMed  Google Scholar 

  19. DiGiuseppe JA, Louje DC, Williams JE et al. Blastic natural killer leukemia/lymphoma: A clinicopathologic study. Am J Surg Pathol 1997; 21: 1223–1230.

    Article  CAS  Google Scholar 

  20. Drénou B, Lamy T, Amiot L et al. CD3−CD56+ Non-Hodgkin's lymphomas with an aggressive behaviour related to multidrug resistance. Blood 1997; 8: 2966–2974.

    Google Scholar 

  21. Uchiyama N, Ito K, Kawai K et al. CD2−, CD4+, CD56+ agranular natural killer cell lymphoma of the skin. Am J Dermatol 1998; 20: 513–517.

    Article  CAS  Google Scholar 

  22. Bagot M, Bouloc A, Charue D et al. Do primary cutaneous non-T non-B CD4+CD56+ lymphomas belong to the myelo-monocytic lineage? (letter). J Invest Dermatol 1998; 11: 1242–1244.

    Article  Google Scholar 

  23. Kameoka J, Ichinohasama R, Tanaka M et al. A cutaneous agranular CD2− CD4+ CD56+ ‘lymphoma’. Am J Clin Pathol 1998; 110: 478–488.

    Article  CAS  Google Scholar 

  24. Bastian BC, Ott G, Müller-Deubert S et al. Primary cutaneous natural killer/T-cell lymphoma. Arch Dermatol 1998; 134: 109–111.

    Article  CAS  Google Scholar 

  25. Ko YH, Kim SH, Ree HJ . Blastic NK-cell lymphoma expressing terminal deoxynucleotidyl transferase with Homer-Wright type pseudorosettes formation. Histopathology 1998; 33: 547–553.

    Article  CAS  Google Scholar 

  26. Mukai HY, Kojima H, Suzukawa K et al. High-dose chemotherapy with peripheral blood stem cell rescue in blastoid Natural Killer cell lymphoma. Leukemia Lymphoma 1999; 32: 583–588.

    Article  CAS  Google Scholar 

  27. Mhawech P, Medeiros J, Bueso-Ramos C et al. Natural killer-cell lymphoma involving the gynecologic tract. Arch Pathol Lab Med 2000; 124: 1510–1513.

    CAS  PubMed  Google Scholar 

  28. Nagatani T, Okazawa H, Kambara T et al. Cutaneous monomorphous CD4- and CD56-positive large-cell lymphoma. Dermatology 2000; 200: 202–208.

    Article  CAS  Google Scholar 

  29. Falcão RP, Garcia AB, Marques MG et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leuk Res 2002; 26: 803–807.

    Article  Google Scholar 

  30. Kojima H, Mukai HY, Shinagawa A et al. Clinicopathological analyses of 5 Japanese patients with CD56+ primary cutaneous lymphomas. Int J Hematol 2000; 72: 477–483.

    CAS  PubMed  Google Scholar 

  31. Ginarte M, Abalde MT, Peteiro C et al. Blastoid NK cell leukemia/lymphoma with cutaneous involvement. Dermatology 2000; 201: 268–271.

    Article  CAS  Google Scholar 

  32. Rakozy C, Mohamed AN, Vo TD et al. CD56+/CD4+ lymphomas and leukemias are morphologically, immunophenotypically, cytogenetically, and clinically diverse. Am J Clin Pathol 2001; 116: 168–176.

    Article  CAS  Google Scholar 

  33. Yamada O, Ichikawa M, Okamoto T et al. Killer T-cell induction in patients with blastic natural killer cell lymphoma/leukaemia: implications for successful treatment and possible therapeutic strategies. Br J Haematol 2001; 113: 153–160.

    Article  CAS  Google Scholar 

  34. Kimura S, Kakazu N, Kuroda J et al. Agranular CD4+CD56+ blastic natural killer leukaemia/lymphoma. Ann Hematol 2001; 80: 228–231.

    Article  CAS  Google Scholar 

  35. Honda S, Ito Y, Otawa M et al. CD56- and CD4-positive non-Hodgkin's lymphoma of probable T-cell origin. Rinsho Ketsueki 2001; 42: 420–425.

    CAS  PubMed  Google Scholar 

  36. Álvarez-Larrán A, Villamor N, Hernández-Boluda JC et al. Blastic natural killer cell leukemia/lymphoma presenting as overt leukaemia. Clin Lymphoma 2001; 2: 178–182.

    Article  Google Scholar 

  37. Kato N, Yasukawa K, Kimura K et al. CD2−CD4+CD56+ hematodermic/hematolymphoid malignancy. J Am Acad Dermatol 2001; 44: 231–238.

    Article  CAS  Google Scholar 

  38. Aoyama Y, Yamane T, Hino M et al. Blastic NK-cell lymphoma/leukemia with T-cell receptor γ rearrangement. Ann Hematol 2001; 80: 752–754.

    Article  CAS  Google Scholar 

  39. Feuillard J, Jacob M-C, Valensi F et al. Clinical and biological features of CD4+CD56+ malignancies. Blood 2002; 99: 1556–1563.

    Article  CAS  Google Scholar 

  40. Khoury JD, Medeiros LJ, Manning JT et al. CD56+ TdT+ Blastic natural killer cell tumor of the skin. A primitive systemic malignancy related to myelomonocytic leukemia. Cancer 2002; 94: 2401–2408.

    Article  CAS  Google Scholar 

  41. Chen N, Agosti S, Doll D . Blastic natural killer cell leukaemia/lymphoma. Br J Haematol 2002; 116: 241.

    Article  Google Scholar 

  42. Chang SE, Choi HJ, Huh J et al. A case of primary cutaneous CD56+, TdT+, CD4+, blastic NK-cell lymphoma in a 19-year-old woman. Am J Dermatopathol 2002; 24: 72–75.

    Article  Google Scholar 

  43. Bayerl MG, Rakozy CK, Mohamed AN et al. Blastic natural killer cell lymphoma/leukemia. Am J Clin Pathol 2002; 11: 41–50.

    Article  Google Scholar 

  44. Leroux D, Mugneret F, Callanan M et al. on behalf of Groupe Français de Cytogénétique Hématologique. CD4, CD56+ DC2 acute leukaemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. Blood 2002; 99: 4154–4159.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Poliklinik, Universitaet Wuerzburg, Wuerzburg, Germany

    P Reimer, D Kraemer, V Kunzmann, F Weissinger & M Wilhelm

  2. Pathologisches Institut, Universitaet Wuerzburg, Wuerzburg, Germany

    T Rüdiger, A Zettl & H Konrad Müller-Hermelink

Authors
  1. P Reimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Rüdiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Kraemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V Kunzmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Weissinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Zettl
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Wilhelm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Reimer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Reimer, P., Rüdiger, T., Kraemer, D. et al. What is CD4+CD56+ malignancy and how should it be treated?. Bone Marrow Transplant 32, 637–646 (2003). https://doi.org/10.1038/sj.bmt.1704215

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704215

Keywords

  • CD4+CD56 malignancy
  • stem cell transplantation
  • chemotherapy

This article is cited by

Search

Advanced search

Quick links